Threshold Pharmaceuticals conducts $30 million at-the-market offering

Company reports equity offering through MLV & Co.

By Devika Patel

Knoxville, Tenn., Aug. 1 – Threshold Pharmaceuticals, Inc. arranged a $30 million at-the-market issuance sales agreement with MLV & Co. LLC, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

The agent will be paid a 3% commission.

Proceeds will be used for working capital and general corporate purposes, including research and development, general and administrative expenses and manufacturing expenses.

Threshold is a biotechnology company based in Redwood City, Calif., that develops small molecule therapeutics for the potential treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.